A patient support program has been established to transition patients to Egrifta WR, which will gradually replace Egrifta SV. Egrifta WR™, a new concentrated formulation (F8) of tesamorelin, is now ...
November 12, 2010 — The US Food and Drug Administration (FDA) has approved tesamorelin acetate injection (Egrifta; Theratechnologies, Inc, and marketed by EMD Serono) as the first and only treatment ...
MONTREAL, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (TH:CA) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today announced the availability of EGRIFTA WR™ (tesamorelin) ...
MONTREAL, March 25, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (TH:CA) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration ...
(RTTNews) - Theratechnologies Inc. (THTX, TH.TO) announced the availability of EGRIFTA WR (tesamorelin) for injection, approved earlier this year by the U.S. Food and Drug Administration, for the ...
HIV patients with end-stage renal disease may need increased nutritional intake. Few studies have looked at this population, but these patients may have very high energy needs. Highly active ...
Bowery Clinic today announced expanded, physician-led protocols centered on two clinically studied peptides that act upstream ...
MONTREAL, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results